1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow 426c.Mod.Core-C4b: new trials by email Literature Review of 426c.Mod.Core-C4b trials Research Report on 426c.Mod.Core-C4b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum) - HIV Infections | Phase 1 | Not yet recruiting | HIV Vaccine Trials Network | 22 | 2027-03-30 | 2026-09-18 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant - HIV | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2025-03-17 | 2025-09-25 |
| The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum - Chronic HIV Infection | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | 2024-01-03 | 2026-01-14 |
HIV Infections (2)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · HIV Vaccine Trials Network (1)
United States (2) · South Africa (1)
Amy Violari (1)
UM1AI068614 (1)